Global Mitoxantrone Market Size, Share and Trends Analysis Report, By Drug Dose (5mg Lyophilized Powder, 20mg/10ml Multidose Vial, 25mg/12.5ml Multidose Vial, and 30 mg/15ml Multidose Vial), By Application (Prostate Cancer, Multiple Sclerosis, and Others), Forecast (2022-2028)

The global mitoxantrone market is anticipated to grow at a significant CAGR 5% during the forecast period (2022-2028). With the increase in the number of prostate cancer cases around the globe, the demand for mitoxantrone has been increased significantly over the years. Prostate cancer was found mostly in the European region, therefore the European region is anticipated to grow in the anticipated period. Mitoxantrone is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. According to the National Multiple Sclerosis Society, Around 1 million US residents are living with multiple sclerosis. Multiple sclerosis is the most widespread disabling neurological condition of young adults around the world. It can develop at any age, it is a potentially disabling disease of the brain and spinal cord. However, most people receive diagnoses between the ages of 20 and 50. There are relapsing, remitting, and progressive types of multiple sclerosis.

Mitoxantrone’s efficacy has been established in patients with breast cancer, leukemia, and lymphoma when used alone or in combination with other chemotherapy medications. Since it is not a vesicant, this medication can be used for locoregional (however not intrathecal) therapy. When compared to doxorubicin, it has a better tolerability profile due to which mitoxantrone is always in demand in the market. Myelotoxicity and mucositis are dose-limiting toxicity. As a result, this medicine has lately been utilized in high doses in conjunction with bone marrow support and hematopoietic growth factors.

Prostate cancer begins when cells in the prostate gland start to grow out of control. The prostate is a gland found only in males. It makes some of the fluid that is part of semen. It is treated with a mitoxantrone drug. The more cancer cell present in the body, the higher the doses of mitoxantrone is given to the patient. According to the American Cancer Society, prostate cancer is the most common cancer in American men. The American Cancer Society’s estimates for prostate cancer in the United States for 2022 are about 268,490 new cases of prostate cancer and about 34,500 deaths from prostate cancer. Therefore, the rising incidences of prostate cancer is accelerating the demand for mitoxantrone.

Some major players in the market include Baxter International, Inc., Novartis International AG, Pfizer Inc., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. Sichuan Sunnyhope Pharmaceutical offers Mitoxantrone HCL in the form of injection. Mitoxantrone Hydrochloride is the hydrochloride salt of an anthracenedione antibiotic with antineoplastic activity. Mitoxantrone intercalates into and crosslinks DNA, thereby disrupting DNA and RNA replication. This agent also binds to topoisomerase II, resulting in DNA strand breaks and inhibition of DNA repair. Mitoxantrone is less cardiotoxic compared to doxorubicin. Therefore, it reduces the cancer cell, which propel the growth in the demand for Mitoxantrone.

Market Coverage

• The market number available for – 2022-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Drug Dose
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Baxter International, Inc., Novartis International AG, Pfizer Inc., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Mitoxantrone Market Report by Segment

By Drug Dose

• 5mg Lyophilized Powder
• 20 mg/10ml Multidose Vial
• 25 mg/12.5ml Multidose Vial
• 30mg/15ml Multidose Vial

By Application

• Prostate Cancer
• Multiple Sclerosis
• Others

Global Mitoxantrone Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

About us:

Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.

Media Contact:

Company name: Orion Market Reports

Contact person: Mr. Anurag Tiwari

Email: info@orionmarketreports.com

Contact no: +91 780-304-0404